Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

Paradis, Daniel; Vallée, François; Allard, S; Bisson, Chantal; Daviau, N; Drapeau, Christine; Auger, François A.; LeBel, Marc

doi:10.1128/aac.36.10.2085

Cited by 65 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ofloxacin and ciprofloxacin, when administered as either single agents or in combination with ceftazidime, exhibited pharmacokinetic parameters consistent with published data (12, . Ceftazidime and piperacillin pharmacokinetics also correlated well with published values (7,17). In contrast, when ofloxacin and ciprofloxacin were combined with piperacillin, a statistically significant reduction in the total body clearance of the quinolones was observed (P Ͻ0.05).…”

Section: Discussionsupporting

confidence: 73%

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

Klepser

Patel

Nicolau

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

On the basis of MIC data, ciprofloxacin exhibits superior activity against Pseudomonas aeruginosa than the other currently available fluoroquinolones do. Despite the antipseudomonal advantage noted for ciprofloxacin monotherapy, it is unknown whether this advantage is maintained when the fluoroquinolones are used in combination with antipseudomonal ␤-lactams such as ceftazidime and piperacillin. Twelve healthy volunteers were enrolled in this open-label, randomized, steady-state, six-way cross-over, comparative trial. All subjects received the following regimens: (i) 400 mg of ofloxacin given intravenously (i.v.) every 12 h (q12h), (ii) 400 mg of ciprofloxacin given i.v. q12h, (iii) 400 mg of ofloxacin given i.v. q12h plus 1 g of ceftazidime given i.v. every 8 h (q8h), (iv) 400 mg of ciprofloxacin given i.v. q12h plus 1 g of ceftazidime given i.v. q8h, (v) 400 mg of ofloxacin given i.v. q12h plus 4 g of piperacillin given i.v. q8h, and (vi) 400 mg of ciprofloxacin given i.v. q12h plus 4 g of piperacillin given i.v. q8h. Serum bactericidal titers with subsequent calculation of the area under the bactericidal curve were determined against three clinical isolates of P. aeruginosa. As monotherapy, ciprofloxacin demonstrated superior antipseudomonal activity than ofloxacin did; however, combination of these agents with ceftazidime yielded remarkably similar and statistically comparable activity profiles. In contrast, ciprofloxacin-piperacillin retained a bactericidal advantage over ofloxacin-piperacillin. Although ciprofloxacin exhibits superior antipseudomonal activity when used as monotherapy, combination of ofloxacin or ciprofloxacin with ceftazidime yielded equivalent activity profiles against susceptible strains of P. aeruginosa.Pseudomonas aeruginosa is a problematic pathogen associated with numerous nosocomial and community-acquired infections. Treatment of infections caused by this microbe is frequently complicated by an intrinsic resistance to numerous antimicrobial agents and by the frequent development of resistance during single-agent therapy. Troublesome resistance profiles coupled with the significant morbidity and mortality associated with pseudomonal infections have prompted many clinicians to utilize combinations of antimicrobial agents to treat infections caused by this pathogen. Historically, combination therapy has consisted of an antipseudomonal ␤-lactam, such as ceftazidime or piperacillin, plus an aminoglycoside. However, the potential for toxicity and the need for parenteral administration have encouraged clinicians to search for therapeutic alternatives to the aminoglycosides.The fluoroquinolones ciprofloxacin and ofloxacin both display in vitro and in vivo activity against P. aeruginosa; however, ciprofloxacin has been reported to be severalfold more active against this microorganism than ofloxacin (10,19,20). Typical MICs of ciprofloxacin and ofloxacin for 90% of P. aeruginosa isolates range from 0.25 to 0.5 g/ml (10, 19) and 2.0 to 4.0 g/ml (10, 20), respectively. However, despite low init...

show abstract

Section: Discussionsupporting

confidence: 73%

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

Klepser

Patel

Nicolau

et al. 1995

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

“…Hsp70 binds tubulin and may directly or indirectly inhibit tubulin polymerization (20)(21)(22). Similarly, Hsp27 binds to actin and inhibits actin polymerization (23,24).…”

Section: Introductionmentioning

confidence: 99%

Geldanamycin Anisimycins Activate Rho and Stimulate Rho- and ROCK-Dependent Actin Stress Fiber Formation

Amiri

Noei

Feroz

et al. 2007

Molecular Cancer Research

View full text Add to dashboard Cite

Heat shock protein 90 (Hsp90) is a member of the heat shock family of molecular chaperones that regulate protein conformation and activity. Hsp90 regulates multiple cell signaling pathways by controlling the abundance and activity of several important protein kinases and cell cycle -related proteins. In this report, we show that inhibition of Hsp90 by geldanamycin or its derivative, 17-allylamino-17-desmethoxygeldamycin, leads to activation of the Rho GTPase and a dramatic increase in actin stress fiber formation in human tumor cell lines. Inactivation of Rho prevents geldanamycininduced actin reorganization. Hsp90 inactivation does not alter the appearance of filopodia or lamellipodia and tubulin architecture is not visibly perturbed. Our observations suggest that Hsp90 has an important and specific role in regulating Rho activity and Rho-dependent actin cytoskeleton remodeling.

show abstract

“…In a number of other studies, various dosages were examined noncomparatively. Van Several studies (3,14,19,25,37) investigated the SBA following oral administration of ciprofloxacin at various doses (mainly 500 and 750 mg). The same trend of good-to-excellent activity against members of the family Enterobacteriaceae, mediocre activity against P. aeruginosa, and poor performance against S. aureus and other gram-positive organisms was observed.…”

mentioning

confidence: 99%

Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously

Dan

Poch

Quassem

et al. 1994

Antimicrob Agents Chemother

View full text Add to dashboard Cite

show abstract

Comparative study of pharmacokinetics and serum bactericidal activities of cefpirome, ceftazidime, ceftriaxone, imipenem, and ciprofloxacin

Cited by 65 publications

References 33 publications

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa

Geldanamycin Anisimycins Activate Rho and Stimulate Rho- and ROCK-Dependent Actin Stress Fiber Formation

Comparative serum bactericidal activities of three doses of ciprofloxacin administered intravenously

Contact Info

Product

Resources

About